Lumakras
Amgen Sees Strong Growth for Precision Oncology Drugs in Q3
Sales for Lumakras and Blincyto in particular soared during the third quarter as the firm's overall revenues climbed 23 percent year over year.
Amgen's Lumakras Combo Scores High Response Rate in First-Line KRAS-Mutant Colorectal Cancer
Premium
Researchers reported at the ESMO Congress that 78 percent of patients responded to front-line treatment with Lumakras, Vectibix, and chemo.
Experts noted, however, there is insufficient evidence to determine which commercially available KRAS G12C inhibitor is the best treatment for brain metastases.
A case series published last month shows the KRAS-inhibiting cancer drug can also improve symptoms in patients with severe blood vessel overgrowth disorders.
The firm's bispecific T-cell engager Blincyto and KRAS inhibitor Lumakras each provided double-digit sales growth in Q2.
Feb 7, 2024